louisbrulenaudet/clinical-trials huggingface dataset:
Clinical trial NCT01977131: Safety Study of Autologous Bone Marrow Stromal Cells With Modification by Hepatocyte Growth Factor to Treat Silicosis
Official title: Phase 1 Study of Autologous Bone Marrow Stromal Cells With Modification by Hepatocyte Growth Factor to Treat Silicosis
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE1
PHASE2
Conditions: Silicosis
Lead sponsor: Guangzhou Municipal Twelfth People's Hospital
Sponsor class: OTHER
First posted: 2013-11-06
Enrollment: 10
Sex: ALL
Minimum age (years): 18
Maximum age (years): 50
Standard ages: ADULT
Accepts healthy volunteers: no
Allocation: NA
Intervention model: SINGLE_GROUP
Primary purpose: TREATMENT

Brief summary: The aim of this study was to analyze the safety, pulmonary function, and imaging changes of patients with silicosis treated with autologous bone marrow stromal cells with modification by hepatocyte growth factor.


Eligibility criteria: Inclusion Criteria:

- age between 18-50, chronic and accelerated silicosis, characterized with a fibrotic increase in the last two years, FEV1 \<60% and \> 40%, FVC \> 60% and SaO2 \>90%

Exclusion Criteria:

- smoking, active tuberculosis or other infections, cancer, auto-immune disorders, hematological, hepatic or cardiac diseases, and pregnancy

Primary outcomes:
measure: Absence of lung deficits during the procedure and/or in the 6 months follow-up
timeFrame: 6 months
Secondary outcomes:
measure: Improvement of pulmonary deficits
timeFrame: 1 year
Other outcomes:
Locations:
Study officials:
References:
citation: Liu WW, Wang HX, Yu W, Bi XY, Chen JY, Chen LZ, Ding L, Han DM, Guo ZK, Lei YX. Treatment of silicosis with hepatocyte growth factor-modified autologous bone marrow stromal cells: a non-randomized study with follow-up. Genet Mol Res. 2015 Sep 9;14(3):10672-81. doi: 10.4238/2015.September.9.7.
Clinical trial NCT03985631: Tai Chi Intervention by Telerehabilitation
Official title: Tai Chi Intervention by Telerehabilitation as an Innovative Solution for Parkinson's Disease Population
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Parkinson Disease
Keywords: Tai Chi
Telerehabilitation
Parkinson Disease
Lead sponsor: Université de Sherbrooke
Sponsor class: OTHER
First posted: 2019-06-14
Enrollment: 2
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NA
Intervention model: SINGLE_GROUP
Intervention model description: Single group receiving the intevention, one evaluation before and 1 one after the intervention period.
Primary purpose: SUPPORTIVE_CARE

Brief summary: Rational : A lot of people in the province of Quebec suffer from Parkinson's disease and they are mostly vulnerable because they gradually lose their autonomy with the worsening of the disease. Physiotherapy was proven to be an effective treatment method for these patients. However, accessibility to care remains a major issue.

Objective: This project aims to establish the clinical feasibility of a Tai chi rehabilitation program through tele rehabilitation to patients suffering of Parkinson's disease.

Methodology : This pilot study will be conduct with a pre/post-test device. Therefore, to reach the objective, an evaluation will be done before the intervention and directly after the end of the 12 weeks program. Also, the obstacles encountered during the interventions will be noted in a logbook.

Benefits: This is a priority research because its aim is to develop a care system that is efficient and accessible for a target population. The results of this study will confirm the possibility to put in place a telerehabilitation program who could reach, on a larger scale, more patients suffering from Parkinson's disease.


Eligibility criteria: Inclusion Criteria:

* to be diagnosed with Parkinson Disease according to the " Movement Disorders Society's diagnostic criteria " for at least 3 years
* Presence of a postural instability measured by the pull test according to Movement Disorders Society-Sponsored revision scale of Unified Parkinson Disease Rating scale " (MDS-UPDRS) with a score to item 3, 12 ≥ 1,
* Have access to Internet
* Have a caregiver available during rehabilitation sessions

Exclusion Criteria:

* Have a une cognitive impairment measured by the " Mini-Mental State Examination " (MMSE), with a total score \< 24.

Primary outcomes:
measure: Change in balance
timeFrame: 3 months
Secondary outcomes:
measure: Change in quality of life
timeFrame: 3 months
measure: Satisfaction with service received
timeFrame: 3 months
Other outcomes:
Locations:
city: Sherbrooke
country: Canada
facility: Université de Sherbrooke
state: Quebec
city: Sherbrooke
country: Canada
facility: Research Centre on Aging
Study officials:
affiliation: Université de Sherbrooke
name: Michel Tousignant, PhD
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT01047631: Role of Exercise in Diastolic Heart Failure
Official title: Relationship of Cardiovascular and Muscular Capacity to Daily Functioning in Frail Older Adults
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Diastolic Heart Failure
Heart Failure With Preserved Ejection Fraction
Lead sponsor: University of Michigan
Sponsor class: OTHER
First posted: 2010-01-13
Enrollment: 50
Sex: ALL
Minimum age (years): 60
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: Diastolic heart failure is now being recognized as a key form of heart failure in older people. The focus of this research is to study ways to improve and maintain physical activity and functioning. This knowledge may improve the health and well-being in people with diastolic heart failure.

Detailed description: The purpose of this project is to better understand how endurance and fatigue relate to performing daily activities and how we might better improve endurance and reduce fatigue through an exercise program.

Eligibility criteria: Inclusion Criteria:

* Age 60 and over
* Evidence of diastolic dysfunction on echocardiogram
* Normal Left Ventricular Function (LVEF≥50%)
* Heart Failure-NYHA Class II/III
* Able and willing to participate in exercise program
* Able to come to Ann Arbor Michigan for testing

Exclusion Criteria:

* Regularly exercising(30 minute per day, 3 times per week)
* Orthopedic or musculoskeletal condition that limits weight bearing
* Uncontrolled atrial fibrillation
* History of heart valve replacement
* Unstable or serious medical condition (ie. on dialysis, oxygen; severe anemia, uncontrolled blood pressure or coronary artery disease)

Primary outcomes:
measure: 6 minute walk
timeFrame: Baseline, 12 weeks, 24 weeks
Secondary outcomes:
Other outcomes:
Locations:
city: Ann Arbor
country: United States
facility: University of Michigan Mobility Research Center
state: Michigan
Study officials:
References:
Clinical trial NCT01329731: Remineralisation of White Spot Lesions by Elmex® gelée in Post-orthodontic Patients
Official title: White Spot Lesion Development in Post-orthodontic Patients Following Weekly Application of a 1.25% Fluoride Gel Compared to Placebo Over 6 Months
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE4
Conditions: Tooth; Lesion, White Spot Lesions
Keywords: white spot lesion
initial caries
fluoride
amine fluoride
orthodontics
remineralization
brackets
Lead sponsor: Gaba International AG
Sponsor class: INDUSTRY
Collaborators: name: PD Dr. Christian Heumann
First posted: 2011-04-06
Enrollment: 48
Sex: ALL
Minimum age (years): 11
Standard ages: CHILD
ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: The aim of this study is to monitor the effect of intraoral topical high fluoride application on the development of white spot lesions (WSL) after orthodontic treatment with multibracket appliances and to compare it to a placebo.


Eligibility criteria: Inclusion Criteria:

* Written informed consent
* Healthy volunteers (≥11 years) scheduled for bracket removal
* ≥ 1 WSL with a modified score 1 or 2 (Gorelick et al. 1982) on UFT at debonding

Exclusion Criteria:

* Known hypersensitivity or allergy to study products and standard toothpaste ingredients and/or dental material used in the present study
* Known hypersensitivity or allergy to placebo gel ingredients
* Alterations in the teeth's enamel, e.g. hypoplasia, fluorosis
* Any illness/condition potentially affecting the study outcome at investigator's discretion
* Known pregnancy or breast feeding during the course of the study

Primary outcomes:
measure: WSL-size change
timeFrame: 12 weeks
Secondary outcomes:
measure: WSL-size change
timeFrame: Baseline up to 24 weeks
measure: WSL-brightness change
timeFrame: Baseline up to 24 weeks
measure: WSL index on all upper front teeth
timeFrame: Baseline up to 24 weeks
measure: Caries activity
timeFrame: Baseline up to 24 weeks
measure: Plaque index (Silness and Löe 1964)on all upper front teeth
timeFrame: Baseline up to 24 weeks
measure: Gingival bleeding index on all upper front teeth
timeFrame: Baseline up to 24 weeks
measure: DMFT index: Dental health of all teeth
timeFrame: Baseline, 24 weeks
Other outcomes:
Locations:
city: Giessen
country: Germany
facility: Poliklinik für Kieferorthopädie, Justus-Liebig-Universität Giessen
Study officials:
References:
citation: Bock NC, Seibold L, Heumann C, Gnandt E, Roder M, Ruf S. Changes in white spot lesions following post-orthodontic weekly application of 1.25 per cent fluoride gel over 6 months-a randomized placebo-controlled clinical trial. Part II: clinical data evaluation. Eur J Orthod. 2017 Apr 1;39(2):144-152. doi: 10.1093/ejo/cjw061.
citation: Bock NC, Seibold L, Heumann C, Gnandt E, Roder M, Ruf S. Changes in white spot lesions following post-orthodontic weekly application of 1.25 per cent fluoride gel over 6 months-a randomized placebo-controlled clinical trial. Part I: photographic data evaluation. Eur J Orthod. 2017 Apr 1;39(2):134-143. doi: 10.1093/ejo/cjw060.
Clinical trial NCT05579431: A Phase 1, First-in-human Study of VX-634
Official title: A Phase 1, First-in-human Study of Safety, Tolerability, and Pharmacokinetics of VX-634
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE1
Conditions: Alpha 1-Antitrypsin Deficiency
Lead sponsor: Vertex Pharmaceuticals Incorporated
Sponsor class: INDUSTRY
First posted: 2022-10-13
Enrollment: 127
Sex: ALL
Minimum age (years): 18
Maximum age (years): 55
Standard ages: ADULT
Accepts healthy volunteers: yes
Allocation: RANDOMIZED
Intervention model: SEQUENTIAL
Primary purpose: TREATMENT

Brief summary: The purpose of this study is to evaluate the safety, tolerability, and pharmacokinetics (PK) of VX-634 at various doses.

Detailed description: This clinical trial information was submitted voluntarily under the applicable law and, therefore, certain submission deadlines may not apply. (That is, clinical trial information for this applicable clinical trial was submitted under section 402(j)(4)(A) of the Public Health Service Act and 42 CFR 11.60 and is not subject to the deadlines established by sections 402(j)(2) and (3) of the Public Health Service Act or 42 CFR 11.24 and 11.44.).

Eligibility criteria: Key Inclusion Criteria:

* Participants of age between 18 to 55 years (inclusive)
* Body mass index (BMI) of 18.0 to 32.0 kilogram per meter square (kg/m\^2)
* A total body weight of more than (\>)50 kg
* Participants of non childbearing potential
* Non smoker or ex-smoker for at least 3 months before screening

Key Exclusion Criteria:

* Any condition possibly affecting drug absorption

Other protocol defined Inclusion/Exclusion criteria may apply.

Primary outcomes:
measure: Part A and B: Safety and Tolerability as Assessed by Number of Participants With Adverse Events (AEs) and Serious Adverse Events (SAEs)
timeFrame: Day 1 up to Day 20
Secondary outcomes:
measure: Part A and B: Maximum Observed Plasma Concentration (Cmax) of VX-634
timeFrame: Day 1 up to Day 20
measure: Part A and B: Area Under the Concentration Versus Time Curve (AUC) of VX-634
timeFrame: Day 1 up to Day 20
measure: Part A and B: Urine Concentration of VX-634
timeFrame: Part A Cohort A3: Days 1 and 5; Part B Cohort B3: Days 1, 10 and 11
Other outcomes:
Locations:
city: Tempe
country: United States
facility: Celerion - Tempe
state: Arizona
city: Gainesville
country: United States
facility: University of Florida
state: Florida
city: Orlando
country: United States
facility: Central Florida Pulmonary Group, P.A.
state: Florida
city: Lenexa
country: United States
facility: ICON Lenexa
state: Kansas
city: Salt Lake City
country: United States
facility: ICON Salt Lake City
state: Utah
Study officials:
References:
Clinical trial NCT02594631: Shock Wave Lithotripsy Versus Visual Cystolitholapaxy in The Management of Patients Presenting With Calcular Acute Urinary Retention: A Randomized Controlled Trial.
Official title: Shock Wave Lithotripsy Versus Visual Cystolitholapaxy in The Management of Patients Presenting With Calcular Acute Urinary Retention: A Randomized Controlled Trial.
Study type: INTERVENTIONAL
Overall status: UNKNOWN
Phase: PHASE4
Conditions: Urinary Calculi
Keywords: Urethral stones
Acute Cacular urinary retention
Extracorporeal Shock Wave Lithotripsy (ESWL)
Visual lithotripsy
bladder stone
Lead sponsor: Mansoura University
Sponsor class: OTHER
First posted: 2015-11-03
Enrollment: 100
Sex: MALE
Minimum age (years): 18
Maximum age (years): 60
Standard ages: ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: The aim of the study is to compare the safety and efficacy of ESWL and visual cystolitholapaxy in management of calcular acute urine retention.

Detailed description: Patients who present with acute urinary retention due to stone in the urethra or urinary bladder will be randomly assigned to receive treatment either by extracorporeal shock wave lithotripsy or by endoscopic visual cystolitholapaxy where patients and stone characteristics will be recorded and the outcome including the intraoperative and postoperative complications and the stone free rate will be also evaluated

Eligibility criteria: Inclusion Criteria:

1. Adult male patients presenting with acute urinary retention due to urethral or urinary bladder stones.
2. with a stone size not more than 2 centimeters in greatest diameter.
3. No more than 2 stones.

Exclusion Criteria:

1. Bladder cancer.
2. Bladder replacement of any type.
3. Infravesical obstruction, due to marked benign prostatic hyperplasia, prostate cancer, stricture urethra or external urethral meatal stenosis.

Primary outcomes:
measure: Stone free rate
timeFrame: 1 week
Secondary outcomes:
measure: Adverse events after the assigned intervention
timeFrame: 1 month
Other outcomes:
Locations:
city: Mansoura
country: Egypt
facility: Urology an Nephrology Center
state: DK
Study officials:
affiliation: Urology and Nephrology Cenetr
name: Ahmed A Shokeir, Prof
role: STUDY_CHAIR
References:
Clinical trial NCT01078831: Intrabronchial Airway Pressures in Intubated Patients During Bronchoscopy
Official title: Intrabronchial Airway Pressures in Intubated Patients During Bronchoscopy Under Volume Controlled (VC) and Pressure Controlled (PC) Ventilation
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Acute Respiratory Distress Syndrome
Acute Lung Injury (ALI)
Lead sponsor: Oslo University Hospital
Sponsor class: OTHER
First posted: 2010-03-02
Enrollment: 20
Sex: ALL
Minimum age (years): 18
Maximum age (years): 85
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: CASE_ONLY
Time perspective: PROSPECTIVE
Sampling method: PROBABILITY_SAMPLE
Study population: ARDS/ALI patients on mechanical ventilation where a therapeutic or diagnostic bronchoscopy has been requested by the staff physician.

Brief summary: The purpose of this study is to examine changes in ventilation and airway pressures during conventional bronchoscopy of intubated patients.

Detailed description: Mechanically ventilated patients often need bronchoscopy as a diagnostic procedure or for visually directed elimination of secretions. Partial endotracheal tube occlusion by the bronchoscope increases airflow resistance. Inhibition of inspiratory flow may be compensated for by augmented inspiratory pressure. Reduced expiratory flow however, cannot be compensated for by most ventilators and could lead to higher airway - and intrathoracic pressures that are not detected by pressure transducers in the ventilator tubing. In this study we compare changes in ventilation, airway pressures, ventilator pressures and blood gases during bronchoscopy of intubated patients in both volume controlled and pressure controlled ventilation. Our hypothesis are that 1) increased resistance in the tube during bronchoscopy leads to high intrabronchial airway pressures when the ventilator is in volume controlled mode, and 2) when the ventilator is in pressure controlled mode, increased resistance in the tube during bronchoscopy leads to reduced Tidal Volume and moderately increased paCO2.

Eligibility criteria: Inclusion Criteria:

* ARDS/ALI patients on mechanical ventilation
* endotracheal tube size 7-9mm
* age \> 18 years
* therapeutic or diagnostic bronchoscopy requested by staff physician

Exclusion Criteria:

* SpO2 \< 90%
* unstable BP
* pneumothorax
* acute cardiovascular disease
* cerebrovascular or other condition that requires stable BP and saturation

Primary outcomes:
measure: Changes in ventilation, airway pressures and blood gases after bronchoscope insertion.
timeFrame: 2 minutes after bronchoscope insertion/ mode change
Secondary outcomes:
Other outcomes:
Locations:
city: Oslo
country: Norway
facility: Oslo University Hospital - Ulleval
Study officials:
affiliation: Oslo University Hospital - Ulleval, Norway
name: Helge Opdahl, MD, PhD
role: STUDY_DIRECTOR
affiliation: Ullevaal University Hospital
name: Ole H Skjønsberg, MD, PhD
role: STUDY_DIRECTOR
affiliation: Ullevaal University Hospital
name: Fredrik Borchsenius, MD
role: STUDY_DIRECTOR
References:
Clinical trial NCT02941731: Evaluating the Bioequivalence of HIP1403 and HGP0919 Suspensions
Official title: An Open-label, Randomized, Single-dose Crossover Study to Evaluate the Pharmacokinetics of HIP1403 in Healthy Male Subjects
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE1
Conditions: Healthy
Lead sponsor: Hanmi Pharmaceutical Company Limited
Sponsor class: INDUSTRY
First posted: 2016-10-21
Enrollment: 32
Sex: MALE
Minimum age (years): 19
Maximum age (years): 45
Standard ages: ADULT
Accepts healthy volunteers: yes
Allocation: RANDOMIZED
Intervention model: CROSSOVER
Primary purpose: TREATMENT

Brief summary: The purpose of this study is to investigate the bioequivalence after administration of HIP1403 and HGP0919 suspensions in healthy male volunteers.

Detailed description: A randomized, open-label, single dose, crossover clinical trial to investigate and compare the pharmacokinetics between HIP1403 and HGP0919 suspensions in healthy male volunteers.

Eligibility criteria: Inclusion Criteria:

1. Healthy male volunteers, age 19 to 45 years.
2. The result of Body Mass Index(BMI) is not less than 18 kg/m2 , no more than 29 kg/m2.
3. Subjects who have ability to comprehend the objectives, contents of study and property of study drug before participating in trial and have willingness to sign of informed consent in writing.

Exclusion Criteria:

1. Presence of medical history or a concurrent disease that may interfere with treatment and safety assessment or completion of this clinical study, including clinically significant disorders in kidney, liver, cardiovascular system, respiratory system, endocrine system, or neuropsychiatric system.
2. Positive serology for HBs antigen, HCV antibody, HIV antigen

Primary outcomes:
measure: Oseltamivir Cmax
timeFrame: 0h(predose), 0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4, 5, 6, 8, 10, 12, 24, 48hours (Total 16)
measure: Oseltamivir AUClast , AUCinf
timeFrame: 0h(predose), 0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4, 5, 6, 8, 10, 12, 24, 48hours (Total 16)
Secondary outcomes:
measure: Oseltamivir Tmax
timeFrame: 0h(predose), 0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4, 5, 6, 8, 10, 12, 24, 48hours (Total 16)
measure: Oseltamivir t1/2
timeFrame: 0h(predose), 0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4, 5, 6, 8, 10, 12, 24, 48hours (Total 16)
measure: Oseltamivir CL/F
timeFrame: 0h(predose), 0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4, 5, 6, 8, 10, 12, 24, 48hours (Total 16)
measure: Oseltamivir Vd/F
timeFrame: 0h(predose), 0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4, 5, 6, 8, 10, 12, 24, 48hours (Total 16)
Other outcomes:
Locations:
city: Seoul
country: Korea, Republic of
facility: Korea University Anam Hospital
Study officials:
affiliation: Korea University Anam Hospital
name: Ji Young Park, MD, PhD
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT04223531: The Natriuretic Peptide Response to Saline Infusion
Official title: The Natriuretic Peptide Response to Saline Infusion
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Obesity
Lead sponsor: Vanderbilt University Medical Center
Sponsor class: OTHER
First posted: 2020-01-10
Enrollment: 18
Sex: ALL
Minimum age (years): 18
Maximum age (years): 65
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Allocation: NA
Intervention model: SINGLE_GROUP
Primary purpose: OTHER

Brief summary: The primary objective is to evaluate the overarching hypothesis that obese and black individuals have relatively lower circulating natriuretic peptide levels compared with lean and white individuals. Conventional clinical assays for measurement of circulating natriuretic peptides display substantial overlap, precluding determination of the basis of the relative natriuretic peptide deficiency previously observed in these groups. We will study lean or obese, black or white, healthy adult subjects with intravenous (IV) saline infusion as a stimulus for natriuretic peptide production and release. We will measure circulating levels of natriuretic peptide isoforms using mass spectrometry that allows the specific identification of proBNP 1-108 and its cleavage product BNP 1-32.


Eligibility criteria: Inclusion Criteria:

* Age between 18 and 65 years;
* BMI between 18 and 25 (lean) or 30 and 40 kg/m2 (obese);
* self-reported race of either black or white;
* otherwise healthy with no chronic comorbidities.

Exclusion Criteria:

* History of diabetes mellitus
* Currently pregnant
* History of cardiac disorder including heart failure, cardiomyopathy, myocardial infarction, coronary revascularization, abnormal stress test, uncontrolled arrhythmia or arrhythmia requiring treatment, congenital heart disease, pericardial disease.
* History of hypertension defined as taking anti-hypertensive medications or untreated hypertension with systolic blood pressure ≥ 140 mm Hg or diastolic blood pressure ≥ 90 mm Hg at most recent clinical visit or screening visit.
* Obstructive lung disease
* History of chronic kidney disease
* History of liver disease or cirrhosis
* Uncontrolled thyroid dysfunction
* History of solid organ transplant
* History of malignancy other than basal or squamous cell skin cancer
* Inability to lie flat for 6 hours

Primary outcomes:
measure: Change in circulating levels of proBNP 1-108 from baseline to 6 hours
timeFrame: Saline infusion will be given for 2 hours (with 4 hour observation) with blood samples collected at hourly intervals for 7 hours total
measure: Change in circulating levels of proBNP 1-32 from baseline to 6 hours
timeFrame: Saline infusion will be given for 2 hours (with 4 hour observation) with blood samples collected at hourly intervals for 7 hours total
Secondary outcomes:
Other outcomes:
Locations:
city: Nashville
country: United States
facility: Vanderbilt Univeristy
state: Tennessee
Study officials:
affiliation: Vanderbilt University Medical Center
name: Deepak K Gupta, MD, MSCI
role: PRINCIPAL_INVESTIGATOR
References: